Covista Inc. (CVSA)
NYSE:CVSA
Want to see CVSA full AI Analyst Report?
Earnings Data
Report Date
Aug 06, 2026After Close (Confirmed)
Period Ending
2026 (Q4)Consensus EPS Forecast
1.94Last Year’s EPS
1.66Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed strong operational and financial momentum: enrollment growth across institutions, improved margins (when adjusting for a one-week timing shift), raised revenue and EPS guidance, robust free cash flow, balance sheet improvement, share repurchases, campus expansion plans, and technology/AI initiatives. Near-term headwinds include an $18M timing impact at Walden that masked stronger underlying results, modest absolute enrollment improvement at Chamberlain this quarter (0.5%), continued investment-driven CapEx and strategic spending, and an expected higher effective tax rate. Overall, the positives (organic growth, margin expansion excluding timing, raised guidance, cash generation, and clear remediation at Chamberlain) outweigh the transitory and execution-related challenges noted.Company Guidance
Revenue Growth and Raised Guidance
Q3 revenue increased 4.5% year-over-year to $487.0M; excluding a one-week Walden timing shift, revenue would have grown 8.4% YoY. Full-year revenue guidance raised to $1.93B–$1.945B (previously $1.90B–$1.94B), implying 8%–9% growth for FY2026.
Improved Profitability and EPS Upside
Consolidated adjusted EBITDA was $127.9M; excluding the Walden timing shift, adjusted EBITDA would have been $145.9M, a 14.2% YoY increase. Company raised adjusted EPS guidance to $7.95–$8.15 (from $7.80–$8.00), representing 19%–22% growth versus prior year.
Strong Enrollment Momentum Across the Platform
Company surpassed 100,000 total students and delivered its 11th consecutive quarter of total enrollment growth. Walden enrollment grew 12.3% YoY to 54,474 (record), Chamberlain enrollment turned positive, up 0.5% to 40,767, and Med/Vet enrollment rose 4.1% to 5,344.
Segment-Level Operational Strength
Walden (excluding timing impact) would have seen revenue +14.7% and adjusted EBITDA +25.5% with a margin of 33.1% (up 280 bps). Med & Vet revenue +8.9% to $103.5M and adjusted EBITDA +20.1% to $27.5M (margin up 250 bps). Chamberlain adjusted EBITDA rose 2.9% to $58.5M and margin expanded 20 bps to 29.7%.
Cash Generation, Strong Balance Sheet and Capital Allocation
Trailing 12-month free cash flow grew 17% to $336M. Net leverage improved to 0.7x and cash & equivalents were $147M. Refinanced a $510M Term Loan B cutting interest by 50 bps and extending maturity to 2033. Repurchased $66M of stock in the quarter.
Operational and Academic Outcomes
Application review time reduced by weeks via process improvements and automation. Academic outcomes strong: 97% first-time residency attainment rate and AUC >98% in the most recent cycle; veterinary placements remain among the top universities in the U.S.
Growth Initiatives: Campus Expansion and New Programs
Six new Chamberlain campuses in active development (first begins teaching in September; two recently received regulatory approval). Walden launched new programs (clinical psychology, behavioral analysis) enrolling >1,400 students and had 7 additional program approvals.
AI and Technology Partnerships
Co-development with Google Cloud on an AI-powered classroom; initial pilots later this year. Over 4,000 learners enrolled in newly launched AI credentials across nursing, medicine and foundational AI. Covista established a Healthcare Readiness AI Council to ground curriculum in clinical practice.
CVSA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
CVSA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 07, 2026 | $117.00 | $133.73 | +14.30% |
Jan 28, 2026 | $115.92 | $107.78 | -7.02% |
Oct 30, 2025 | $141.77 | $98.02 | -30.86% |
Jun 30, 2025 | $127.23 | $124.40 | -2.22% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Covista Inc. (CVSA) report earnings?
Covista Inc. (CVSA) is schdueled to report earning on Aug 06, 2026, After Close (Confirmed).
What is Covista Inc. (CVSA) earnings time?
Covista Inc. (CVSA) earnings time is at Aug 06, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CVSA EPS forecast?
CVSA EPS forecast for the fiscal quarter 2026 (Q4) is 1.94.